426 related articles for article (PubMed ID: 11402436)
1. Tamoxifen to raloxifene and beyond.
O'Regan RM; Jordan VC
Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen-receptor modulators in 2001.
O'Regan RM; Gradishar WJ
Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
4. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
5. Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Bentrem DJ; Jordan VC
Curr Opin Obstet Gynecol; 2002 Feb; 14(1):5-12. PubMed ID: 11801870
[TBL] [Abstract][Full Text] [Related]
6. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
7. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
9. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Dickler MN; Norton L
Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
11. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
O'Regan RM; Jordan VC
Lancet Oncol; 2002 Apr; 3(4):207-14. PubMed ID: 12067682
[TBL] [Abstract][Full Text] [Related]
12. SERMs for the treatment and prevention of breast cancer.
Swaby RF; Sharma CG; Jordan VC
Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
14. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
15. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
16. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
17. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene in breast cancer prevention.
Gennari L; Merlotti D; Paola VD; Nuti R
Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Rohatgi N; Blau R; Lower EE
J Womens Health Gend Based Med; 2002 Apr; 11(3):291-301. PubMed ID: 11988138
[TBL] [Abstract][Full Text] [Related]
20. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
